View of Phase I/II study of c-MET inhibitor (DE605) combined with sorafenib in patients with advanced hepatocellular carcinoma

Return to Article Details Phase I/II study of c-MET inhibitor (DE605) combined with sorafenib in patients with advanced hepatocellular carcinoma Download Download PDF